Anavex Life Sciences Corp (FRA:12X1)
€ 3.495 0.164 (4.92%) Market Cap: 299.15 Mil Enterprise Value: 165.79 Mil PE Ratio: 0 PB Ratio: 2.31 GF Score: 34/100

Anavex Life Sciences Corp at JPMorgan Healthcare Conference Transcript

Jan 12, 2023 / 04:15PM GMT
Release Date Price: €10.16 (+7.00%)
Unidentified Analyst

Good morning, everyone, and thanks again for attending the 41st JPMorgan Healthcare Investment Banking Conference. My name is (inaudible). I'm an associate with the health care team based in New York. And before we start, as most of you know by now, this presentation will be followed by a Q&A session to the extent time allows.

Today, I'm pleased to introduce Dr. Christopher Missling, President and Chief Executive Officer of Anavex Life Sciences. I'm sure he's very excited to tell you more about this company and the amazing work his team has been doing to improve the lives of patients by developing novel, small medical treatments for some of the most challenging CNS diseases facing society today.

With that, I'll pass it to Dr. Missling to share his story.

Christopher U. Missling
Anavex Life Sciences Corp. - Chairman, President, CEO & Secretary

Thank you very much for the very kind introduction. And I'd like to -- it's great to be here. I'd like to thank first JPMorgan for the kind invitation today.

And let me

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot